63.1% of NNP. ABBREVIATION & OUR PROJECTSFINANCIAL PERFORMANCE FINANCIAL POSITION PROGRESS OF PROJECTS UNDER CONSTRUCTION EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’2017 6M’2018 % change Q1’2018 Q2’2018
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 9M’18 9M’19 change Q3’18 Q2’19 Q3’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 26,652 32,874 23.3% 9,691 10,866 11,751 21.3
EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 6M’18 6M’19 change Q2’18 Q1’19 Q2’19 change change Btmn Btmn y-on-y Btmn Btmn Btmn y-on-y q-on-q Sales and service income 16,961 21,123 24.5% 8,805 10,257 10,866 23.4
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
–2021 Balance by Quarter Change Q2–21 Q1–21 Q2–20 Q2–21 VS Q1–21 Q2–21 VS Q2–20 (Million Baht: MB) (MB) % (MB) % Total revenue 2,081.2 1,824.2 1,187.6 257.0 14.1 893.6 75.2 Total operating expenses
instruction, procedure and technical production, production flow, machine standardization, raw material standardization, diagnostic, testing and process control including the procedure and patent and other
results in creating, altering, transferring, reserving or extinction of client’s right in his/her own asset, without or fail to comply with instruction or consent in writing from the client or any person
act which results in creating, altering, transferring, reserving or extinction of client’s right in his/her own asset, without or fail to comply with instruction or consent in writing from the client or
, transferring, reserving or extinction of client’s right in his/her own asset, without or fail to comply with instruction or consent in writing from the client or any person authorized in writing from the